Phase III results of olaparib for BRCA breast cancer

Tivantinib as second line therapy for high-MET HCC

3 or 6 months adjuvant oxaliplatin for colorectal cancer

No link between pregnancy and breast cancer relapse

Cancer and caring in modern medicine

Pooled analysis of avelumab for metastatic urothelial carcinoma

Cancer and living meaningfully: the CALM intervention

Larotrectinib shows durable efficacy across diverse paediatric and adult cancers

Routine genomic testing is feasible, but only a subset of patients benefit

Molecular profiles and the future of adjuvant therapy

Pregnancy after breast cancer no associated with relapse risk

Recent childhood cancer survivors face less chronic disease risk than previous decades